ArticleBiomacromolecules2026
Polypeptide Sequence Effects on Virus Thermostability in Complex Coacervate Formulations.
Article in Biomacromolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Current vaccine formulations heavily rely on cold chains to avoid degradation during transportation and storage. Vaccines typically degrade when exposed to temperatures outside the 2-8 °C range, leading to waste and logistical challenges, particularly in rural areas. This study investigates the ability of poly(lysine)- and poly(glutamate)-based peptide coacervates to improve the thermal stability of porcine parvovirus (PPV), a model nonenveloped viral vaccine. We hypothesized that both the length and specific amino acid sequence of the peptides forming the coacervates would influence the stability of PPV. Long polypeptides (400-800 mers) provided significant protection, slowing PPV inactivation at 60 °C for up to 7 days by as much as 4 logs (10,000-fold), whereas shorter 48-mer homopolypeptides offered limited stability. Modifying peptide sequences revealed that glutamate-glycine block copolypeptides at larger block sizes improved thermostability, while incorporating alanine residues into lysine block copolypeptides improved stabilization beyond that achieved with long homopolypeptides. The addition of sucrose in the formulations further improved thermostability, while trehalose showed minimal benefit. Although coacervation did not have a significant impact on viral infectivity, in vivo studies leveraging an alum adjuvant demonstrated that PPV released from a coacervate yielded lower antibody responses compared to native virus, indicating the presence of complicating interactions that potentially masked the immunogenic epitopes on the capsid surface or decreased the effectiveness of the adjuvant. Overall, this study showed that coacervate formulations can be adjusted to enhance virus thermal stability; however, further work is necessary to understand how such formulations can provide thermostability without altering the immune response necessary for a successful vaccine. Such design principles would enable the development of formulations that could decrease the vaccine cold-chain dependence and improve vaccine accessibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.